Clinuvel Pharmaceuticals Limited

Research Clinuvel Pharmaceuticals Limited (UR9) on Bullrun: market cap EUR 287.44M, P/E 14.6, dividend yield 0.5%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerUR9
• ExchangeF
• CountryAustralia
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Market capEUR 287.44M
• P/E14.6
• Dividend yield0.5%
• Financial periodFY2025
• RevenueEUR 95.02M
• Revenue growth7.8%
• Net incomeEUR 36.17M
• Free cash flowEUR 40.80M
• Gross margin83.3%

Valuation Snapshot

latest market cap is EUR 287.44M; P/E is 14.6; dividend yield is 0.5%.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).

Frequently asked questions

What is Clinuvel Pharmaceuticals Limited's market cap?

Clinuvel Pharmaceuticals Limited's market capitalization is EUR 287.44M.

What is Clinuvel Pharmaceuticals Limited's P/E ratio?

Clinuvel Pharmaceuticals Limited's price-to-earnings (P/E) ratio is 14.6.

Does Clinuvel Pharmaceuticals Limited pay a dividend?

Clinuvel Pharmaceuticals Limited has a dividend yield of 0.5%.

What does Clinuvel Pharmaceuticals Limited do?

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.